Novelix Pharma Puts Capital On The Table, Board To Weigh Preferential Issue

Novelix Pharmaceuticals has convened a board meeting on June 4, 2026 to consider a preferential issue of securities, signalling an imminent capital-raising move by the Hyderabad-based drugmaker. The proposed issue will be structured in line with the Companies Act and SEBI’s ICDR norms, subject to shareholder and regulatory approvals.  

In a regulatory filing, the company said its board will meet at the registered office to evaluate issuance of securities on a preferential basis and related enabling resolutions. Alongside, directors will finalise the notice, date, time and venue of an extraordinary general meeting (EGM) where shareholders will vote on the capital-raising proposal.  

Board Agenda And Capital Raise Framework

Compliance And Trading Window Closure

Key highlights  

• Board meeting scheduled on June 4, 2026 to consider preferential issue of securities  
• Issue to be structured under Companies Act and SEBI ICDR Regulations  
• EGM notice, schedule and scrutiniser appointment also on the agenda  
• Trading window closed for insiders from June 1 until 48 hours post outcome  
• Details on size, structure and investors to be announced after board approval  
  
  

Sources: Novelix Pharmaceuticals Limited prior intimation of board meeting filed with BSE